President Trump just secured a groundbreaking deal with AstraZeneca that will force the pharmaceutical giant to offer American Medicaid patients the same low drug prices other countries enjoy.

Story Highlights

• AstraZeneca agrees to most-favored-nation pricing for U.S. Medicaid patients, matching lowest global prices
• Up to 80% discounts for Americans with chronic diseases like asthma and COPD through new TrumpRx platform
• $50 billion investment in U.S. manufacturing and R&D by 2030, creating thousands of American jobs
• Three-year tariff waiver incentivizes domestic production shift, strengthening supply chain independence

Trump Delivers on America First Drug Pricing

President Trump announced October 10th that AstraZeneca committed to providing U.S. Medicaid patients prescription drugs at most-favored-nation pricing, ensuring Americans pay no more than patients in other developed countries. This landmark agreement follows Trump’s September deal with Pfizer, demonstrating his administration’s successful strategy of leveraging American market power to stop pharmaceutical companies from treating U.S. patients as cash cows while offering better deals abroad.

The deal includes immediate discounts up to 80% for eligible patients with chronic diseases, directly addressing the healthcare cost crisis that has burdened American families for decades. Secretary Robert F. Kennedy Jr. called the agreement “really monumental,” highlighting how the administration used unprecedented leverage to secure concessions from the major European pharmaceutical company that previous administrations failed to achieve.

Trump Cuts a Deal With AstraZeneca to Lower Drug Prices – The New York Times https://t.co/AP7wcSCW1F

— Felix (@Felix1367634) October 11, 2025

TrumpRx Platform Brings Price Transparency Revolution

AstraZeneca will list all primary care medications on the new TrumpRx government website launching early 2026, providing unprecedented price transparency for American consumers. CMS Administrator Dr. Mehmet Oz predicted that “95% of medications will be available to the public at most-favored prices” as more companies join this initiative, fundamentally reshaping how Americans access affordable prescription drugs.

This transparent pricing model represents a direct assault on the pharmaceutical industry’s decades-long practice of obscuring drug costs and exploiting American patients. The platform will empower consumers with real pricing information, allowing them to make informed healthcare decisions without navigating the complex web of insurance networks and hidden pharmaceutical pricing schemes that have enriched corporations at patients’ expense.

Watch: BREAKING NEWS: Trump Announces Deal With AstraZeneca To Offer U.S. ‘Most Favored Nation’ Prices

Massive Manufacturing Investment Strengthens American Independence

AstraZeneca committed to investing $50 billion in U.S. manufacturing and research by 2030, including a new $4.5 billion facility in Virginia that will create thousands of high-paying American jobs. This investment addresses critical supply chain vulnerabilities exposed during the COVID-19 pandemic, when foreign-manufactured drug shortages threatened American patients while pharmaceutical companies prioritized profits over national security considerations.

The three-year pharmaceutical tariff waiver provides AstraZeneca time to shift production domestically, incentivizing reshoring that strengthens American manufacturing capabilities while reducing dependence on foreign supply chains. This approach demonstrates how strategic trade policy can achieve both immediate consumer benefits and long-term national security objectives, contrasting sharply with previous administrations that allowed pharmaceutical companies to exploit American markets while manufacturing critical medications overseas.

Sources:

Trump strikes deal with AstraZeneca on drug pricing – STAT News
Trump announces AstraZeneca deal to lower drug prices for Medicaid patients – CBS News
FACT SHEET: President Donald J. Trump Announces Second Deal to Bring Most-Favored Nation Pricing to American Patients – White House
AstraZeneca, White House Set to Agree to Most-Favored Nation Deal – Pharmacy Times